» Articles » PMID: 16931909

Urokinase-receptor (u-PAR): an Essential Player in Multiple Games of Cancer: a Review on Its Role in Tumor Progression, Invasion, Metastasis, Proliferation/dormancy, Clinical Outcome and Minimal Residual Disease

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2006 Aug 26
PMID 16931909
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The relevance of the u-PA system in mediating tumor-associated proteolysis, invasion and metastasis, amongst other phenomena associated with tumor progression, has been clearly demonstrated in diverse cancer entities. This review will update on the biological and clinical relevance of the urokinase-receptor (u-PAR). Specifically, the article focuses on the potential importance of u-PAR for the development of minimal residual disease in solid cancer, and in this context reviews the biological relevance of the u-PAR for tumor cell dormancy. Furthermore, transcriptional mechanisms regulating u-PAR in vitro and in vivo, and their potential clinical and therapeutic relevance in gastrointestinal cancers, are elucidated.

Citing Articles

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.

Tincknell G, Piper A, Aghmesheh M, Becker T, Vine K, Brungs D Cancers (Basel). 2021; 13(16).

PMID: 34439251 PMC: 8393967. DOI: 10.3390/cancers13164097.


High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray.

Feng X, Zhang L, Ke S, Liu T, Hao L, Zhao P Oncol Lett. 2020; 20(3):2356-2368.

PMID: 32782553 PMC: 7400985. DOI: 10.3892/ol.2020.11787.


Global transcriptomic analysis identifies as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.

Xu B, Bai Z, Yin J, Zhang Z PeerJ. 2019; 7:e7091.

PMID: 31218131 PMC: 6563800. DOI: 10.7717/peerj.7091.


Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis.

Yu Y, Wang H, Yan A, Wang H, Li X, Liu J BMC Cancer. 2018; 18(1):383.

PMID: 29618336 PMC: 5885417. DOI: 10.1186/s12885-018-4230-z.


Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model.

Zhou H, Wang H, Yu G, Wang Z, Zheng X, Duan H Oncol Lett. 2017; 14(5):5189-5196.

PMID: 29113154 PMC: 5656026. DOI: 10.3892/ol.2017.6896.